Risk of Cardiovascular Events in Schizophrenic Patients Treated with Paliperidone Palmitate Once-Monthly Injection (PP1M): A Population-Based Retrospective Cohort Study in Taiwan
ConclusionThis study reported the population-based incidence of cardiovascular events in schizophrenic patients initiating PP1M treatment. PP1M was not associated with increased risks of serious cardiovascular events but was potentially associated with lower risks of cardiovascular hospitalizations compared with oral SGAs.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research
More News: Arrhythmia | Cardiology | Cardiovascular | Databases & Libraries | Disability | Drugs & Pharmacology | Health Insurance | Heart | Insurance | Invega | Invega Sustenna | Ischemic Stroke | Schizophrenia | Stroke | Study | Taiwan Health | Ventricular Arrhythmia